Search
Magnesium gluconate
go.drugbank.com/drugs/DB13749ApprovedWithdrawnAlthough magnesium is available in the form of sulphates, lactate, hydroxide, oxide and chloride, only magnesium gluconate is recommended for magnesium supplementation as it appears to be better absorbed … Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an ingredient in some medicines (such as antacids
Fexofenadine
go.drugbank.com/drugs/DB00950ApprovedInvestigational[L4269] It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation … Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms.
Dexibuprofen
go.drugbank.com/drugs/DB09213ApprovedWithdrawnIt is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. … Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259].
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigationala procedure by increasing platelet counts to the optimal level ≥50,000 per microliter. … [L2932] In July 2025, the FDA expanded approval to include a new pediatric formulation, Doptelet Sprinkle (avatrombopag oral granules), specifically designed for children aged one to less than six years
Paraldehyde
go.drugbank.com/drugs/DB09117ApprovedWithdrawnParaldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. … It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties.
Lumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigational[L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently … [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993]
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalIn order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.
Difamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigational[L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production … The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States.
Botulinum toxin type A
go.drugbank.com/drugs/DB00083ApprovedInvestigationalIn 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. … [A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm